{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:44:22Z","timestamp":1792601062928,"version":"4.5.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Pierre Fabre Dermo-Cosm\u00e9tique & Personal Care"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s13555-026-01792-0","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T18:40:42Z","timestamp":1780684842000},"page":"3345-3360","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Hair Loss in Patients on Glucagon-Like Peptide\u00a01 Receptor Agonists: Understanding Risks and Managing Outcomes"],"prefix":"10.1007","volume":"16","author":[{"given":"Bianca Maria","family":"Piraccini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Va\u00f1\u00f3-Galv\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Blume-Peytavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Ribet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8585-3974","authenticated-orcid":false,"given":"Val\u00e9rie","family":"Mengeaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"1792_CR1","doi-asserted-by":"publisher","first-page":"e076410","DOI":"10.1136\/bmj-2023-076410","volume":"384","author":"H Yao","year":"2024","unstructured":"Yao H, Zhang A, Li D, et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type\u00a02 diabetes: systematic review and network meta-analysis. BMJ. 2024;384:e076410. https:\/\/doi.org\/10.1136\/bmj-2023-076410.","journal-title":"BMJ"},{"issue":"1","key":"1792_CR2","doi-asserted-by":"publisher","first-page":"24103","DOI":"10.1038\/s41598-025-09807-0","volume":"15","author":"X Ren","year":"2025","unstructured":"Ren X, Hua H, Wu Y, et al. Efficacy and safety of GLP-1 agonists in the treatment of T2DM: a systematic review and network meta-analysis. Sci Rep. 2025;15(1):24103. https:\/\/doi.org\/10.1038\/s41598-025-09807-0.","journal-title":"Sci Rep"},{"key":"1792_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/SKHT8119","volume":"25","author":"M Nunns","year":"2025","unstructured":"Nunns M, Febrey S, Buckland J, et al. The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review. Health Technol Assess. 2025;25:1\u201373. https:\/\/doi.org\/10.3310\/SKHT8119.","journal-title":"Health Technol Assess"},{"issue":"11","key":"1792_CR4","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1007\/s13555-025-01537-5","volume":"15","author":"S Cedirian","year":"2025","unstructured":"Cedirian S, Donati M, Rapparini L, et al. Benefit-risk assessment of GLP-1 receptor agonists: implications for dermatologists and plastic surgeons. Dermatol Ther (Heidelb). 2025;15(11):3173\u201393. https:\/\/doi.org\/10.1007\/s13555-025-01537-5.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1792_CR5","doi-asserted-by":"publisher","first-page":"ojaf056","DOI":"10.1093\/asjof\/ojaf056","volume":"7","author":"G Daneshgaran","year":"2025","unstructured":"Daneshgaran G, Shauly O, Gould DJ. \u201cOzempic face\u201d in plastic surgery: a systematic review of the literature on GLP-1 receptor agonist mediated weight loss and analysis of public perceptions. Aesthet Surg J Open Forum. 2025;7:ojaf056. https:\/\/doi.org\/10.1093\/asjof\/ojaf056.","journal-title":"Aesthet Surg J Open Forum"},{"issue":"5","key":"1792_CR6","doi-asserted-by":"publisher","first-page":"e321","DOI":"10.1111\/jdv.70088","volume":"40","author":"JM Camino-Salvador","year":"2026","unstructured":"Camino-Salvador JM, Rodr\u00edguez-Cuadrado FJ, Pinto-Pulido EL, Fern\u00e1ndez-Parrado M. Glucagon-like peptide-1 receptor agonists and hair loss: an emerging clinical concern. J Eur Acad Dermatol Venereol. 2026;40(5):e321\u20133. https:\/\/doi.org\/10.1111\/jdv.70088.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1792_CR7","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jaad.2020.06.047","volume":"85","author":"A Toussi","year":"2021","unstructured":"Toussi A, Barton VR, Le ST, Agbai ON, Kiuru M. Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: a systematic review. J Am Acad Dermatol. 2021;85(1):162\u201375. https:\/\/doi.org\/10.1016\/j.jaad.2020.06.047.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"1792_CR8","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1001\/jamadermatol.2021.2196","volume":"157","author":"CH Huang","year":"2021","unstructured":"Huang CH, Fu Y, Chi CC. Health-related quality of life, depression, and self-esteem in patients with androgenetic alopecia: a systematic review and meta-analysis. JAMA Dermatol. 2021;157(8):963\u201370. https:\/\/doi.org\/10.1001\/jamadermatol.2021.2196.","journal-title":"JAMA Dermatol"},{"key":"1792_CR9","unstructured":"IQVIA. IQVIA Forecast Link: Sales 2021\u20132025. https:\/\/www.iqvia.com. Accessed 24 Nov 2025."},{"issue":"1","key":"1792_CR10","doi-asserted-by":"publisher","first-page":"e462","DOI":"10.1002\/edm2.462","volume":"7","author":"Z Mariam","year":"2024","unstructured":"Mariam Z, Niazi SK. Glucagon-like peptide agonists: a prospective review. Endocrinol Diabetes Metab Case Rep. 2024;7(1):e462. https:\/\/doi.org\/10.1002\/edm2.462.","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"4","key":"1792_CR11","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","volume":"27","author":"DJ Drucker","year":"2018","unstructured":"Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740\u201356. https:\/\/doi.org\/10.1016\/j.cmet.2018.03.001.","journal-title":"Cell Metab"},{"key":"1792_CR12","doi-asserted-by":"publisher","unstructured":"DeVore S, Reimer H, Meihofer A, et al. A systematic review of the cutaneous adverse effects of GLP-1 agonists. https:\/\/doi.org\/10.20431\/2456-0022.0802005.","DOI":"10.20431\/2456-0022.0802005"},{"key":"1792_CR13","doi-asserted-by":"publisher","first-page":"1431292","DOI":"10.3389\/fendo.2024.1431292","volume":"15","author":"QK Liu","year":"2024","unstructured":"Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists. Front Endocrinol (Lausanne). 2024;15:1431292. https:\/\/doi.org\/10.3389\/fendo.2024.1431292.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1792_CR14","doi-asserted-by":"publisher","first-page":"102661","DOI":"10.1016\/j.eclinm.2024.102661","volume":"73","author":"H Moll","year":"2024","unstructured":"Moll H, Frey E, Gerber P, et al. GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit-harm modelling study. EClinicalMedicine. 2024;73:102661. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102661.","journal-title":"EClinicalMedicine"},{"issue":"2","key":"1792_CR15","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ando.2020.12.009","volume":"82","author":"C Le Pen","year":"2021","unstructured":"Le Pen C, Bauduceau B, Ansolabehere X, et al. Penetration rates of new pharmaceutical products in Europe: a comparative study of several classes recently launched in type-2 diabetes. Ann Endocrinol (Paris). 2021;82(2):99\u2013106. https:\/\/doi.org\/10.1016\/j.ando.2020.12.009.","journal-title":"Ann Endocrinol (Paris)"},{"issue":"9","key":"1792_CR16","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.jval.2025.06.001","volume":"28","author":"N du Soulier","year":"2025","unstructured":"du Soulier N, Pariente A, Bezin J, Grenet G, Faillie JL, de Germay S. Use and potential misuse of glucagon-like peptide-1 receptor agonists in France: a nationwide cohort study. Value Health. 2025;28(9):1335\u201343. https:\/\/doi.org\/10.1016\/j.jval.2025.06.001.","journal-title":"Value Health"},{"issue":"8","key":"1792_CR17","doi-asserted-by":"publisher","first-page":"105724","DOI":"10.1016\/j.jamda.2025.105724","volume":"26","author":"A Zeyfang","year":"2025","unstructured":"Zeyfang A, G\u00f6lz S, Iraci F, et al. Pattern of antidiabetic drug prescription in older persons with type\u00a02 diabetes: results from the German DPV Registry. J Am Med Dir Assoc. 2025;26(8):105724. https:\/\/doi.org\/10.1016\/j.jamda.2025.105724.","journal-title":"J Am Med Dir Assoc"},{"issue":"11","key":"1792_CR18","doi-asserted-by":"publisher","first-page":"4996","DOI":"10.1111\/dom.15912","volume":"26","author":"A Potteg\u00e5rd","year":"2024","unstructured":"Potteg\u00e5rd A, Andersen JH, S\u00f8ndergaard J, et al. Treatment trajectories for Danish individuals with type\u00a02 diabetes in the era of emerging glucose-lowering therapies. Diabetes Obes Metab. 2024;26(11):4996\u20135004. https:\/\/doi.org\/10.1111\/dom.15912.","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"1792_CR19","first-page":"e181","volume":"23","author":"BE Ituarte","year":"2024","unstructured":"Ituarte BE, Taylor MA, Thomas SI, et al. Cross- sectional analysis of adverse dermatologic events reported to the FDA after use of GLP-1 agonists. J Drugs Dermatol. 2024;23(9):e181\u20132.","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"1792_CR20","doi-asserted-by":"publisher","first-page":"413","DOI":"10.36849\/JDD.8605","volume":"24","author":"S Daniel","year":"2025","unstructured":"Daniel S, Waggett S, Lyles E, et al. A retrospective comparative analysis of cutaneous adverse reactions in GLP-1 agonist therapies. J Drugs Dermatol. 2025;24(4):413\u20135. https:\/\/doi.org\/10.36849\/JDD.8605.","journal-title":"J Drugs Dermatol"},{"key":"1792_CR21","doi-asserted-by":"publisher","unstructured":"Fattahi A, Salako K. Dermatological adverse reactions and therapeutic potential of semaglutide, liraglutide and tirzepatide: analysis of UK pharmacovigilance data and literature review. Authorea. 2025. https:\/\/doi.org\/10.22541\/au.175521972.20484170\/v1.","DOI":"10.22541\/au.175521972.20484170\/v1"},{"issue":"1","key":"1792_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.36849\/JDD.9448","volume":"25","author":"MN Fat","year":"2026","unstructured":"Fat MN, Johnson HC, Farberg AS. Cutaneous adverse events associated with GLP-1 receptor agonists: a FAERS database analysis from 2018-2024. J Drugs Dermatol. 2026;25(1):11\u20136. https:\/\/doi.org\/10.36849\/JDD.9448.","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"1792_CR23","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1111\/jdv.20197","volume":"39","author":"H Godfrey","year":"2025","unstructured":"Godfrey H, Leibovit-Reiben Z, Jedlowski P, Thiede R. Alopecia associated with the use of semaglutide and tirzepatide: a disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023. J Eur Acad Dermatol Venereol. 2025;39(2):e153\u20134. https:\/\/doi.org\/10.1111\/jdv.20197.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1792_CR24","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1111\/dom.16376","volume":"27","author":"TH Kim","year":"2025","unstructured":"Kim TH, Lee K, Park S, et al. Adverse drug reaction patterns of GLP-1 receptor agonists approved for obesity treatment: disproportionality analysis from global pharmacovigilance database. Diabetes Obes Metab. 2025;27(6):3490\u2013502. https:\/\/doi.org\/10.1111\/dom.16376.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"1792_CR25","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1007\/s10557-024-07613-w","volume":"39","author":"M Nakhla","year":"2025","unstructured":"Nakhla M, Nair A, Balani P, et al. Risk of suicide, hair loss, and aspiration with GLP1-receptor agonists and other diabetic agents: a real-world pharmacovigilance study. Cardiovasc Drugs Ther. 2025;39(6):1331\u201341. https:\/\/doi.org\/10.1007\/s10557-024-07613-w.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"5","key":"1792_CR26","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.jaad.2025.01.046","volume":"92","author":"O Burke","year":"2025","unstructured":"Burke O, Sa B, Cespedes DA, Sechi A, Tosti A. Glucagon-like peptide-1 receptor agonist medications and hair loss: a retrospective cohort study. J Am Acad Dermatol. 2025;92(5):1141\u20133. https:\/\/doi.org\/10.1016\/j.jaad.2025.01.046.","journal-title":"J Am Acad Dermatol"},{"key":"1792_CR27","doi-asserted-by":"publisher","unstructured":"Sodhi M, Rezaeianzadeh R, Kezouh A, Frey C, Etminan M. Risk of hair loss with semaglutide for weight loss. 2025. medRxiv. https:\/\/doi.org\/10.1101\/2025.02.23.25322568.","DOI":"10.1101\/2025.02.23.25322568"},{"key":"1792_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jvc2.70208","volume":"30","author":"LM Ching","year":"2025","unstructured":"Ching LM, Guirguis CA, Tung JK. Associations between GLP-1 receptor agonists and alopecia: a multi-centre retrospective analysis and public interest trends. JEADV Clin Pract. 2025;30:1\u20135. https:\/\/doi.org\/10.1002\/jvc2.70208.","journal-title":"JEADV Clin Pract"},{"key":"1792_CR29","doi-asserted-by":"publisher","unstructured":"Sodhi M, Rezaeianzadeh R, Kezouh A, Frey C, Etminan M. Risk of alopecia areata with glucagon-like peptide-1 receptor agonists for weight loss. 2025. medRxiv. https:\/\/doi.org\/10.1101\/2025.02.23.25322568.","DOI":"10.1101\/2025.02.23.25322568"},{"issue":"11","key":"1792_CR30","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1111\/ijd.17971","volume":"64","author":"A Singal","year":"2025","unstructured":"Singal A, Ong MM, Neubauer Z, Lipner SR. Association between androgenetic alopecia and glucagon-like peptide-1 receptor treatment in type\u00a02 diabetes mellitus patients: a retrospective cohort study. Int J Dermatol. 2025;64(11):2157\u20139. https:\/\/doi.org\/10.1111\/ijd.17971.","journal-title":"Int J Dermatol"},{"issue":"6","key":"1792_CR31","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/j.jaad.2025.08.033","volume":"93","author":"Z Neubauer","year":"2025","unstructured":"Neubauer Z, Ong MM, Singal A, Lipner SR. Increased risk of telogen effluvium with tirzepatide compared to other weight loss medications: a retrospective cohort TriNetX database study. J Am Acad Dermatol. 2025;93(6):1612\u20134. https:\/\/doi.org\/10.1016\/j.jaad.2025.08.033.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1792_CR32","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","volume":"5","author":"C Sorli","year":"2017","unstructured":"Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type\u00a02 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase\u00a03a trial. Lancet Diabetes Endocrinol. 2017;5(4):251\u201360. https:\/\/doi.org\/10.1016\/S2213-8587(17)30013-X.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"1792_CR33","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","volume":"5","author":"B Ahr\u00e9n","year":"2017","unstructured":"Ahr\u00e9n B, Masmiquel L, Kumar H, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type\u00a02 diabetes (SUSTAIN 2): a 56-week, double-blind, phase\u00a03a, randomised trial. Lancet Diabetes Endocrinol. 2017;5(5):341\u201354. https:\/\/doi.org\/10.1016\/S2213-8587(17)30092-X.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"1792_CR34","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.2337\/dc19-0749","volume":"42","author":"VR Aroda","year":"2019","unstructured":"Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type\u00a02 diabetes. Diabetes Care. 2019;42(9):1724\u201332. https:\/\/doi.org\/10.2337\/dc19-0749.","journal-title":"Diabetes Care"},{"issue":"11","key":"1792_CR35","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989\u20131002. https:\/\/doi.org\/10.1056\/NEJMoa2032183.","journal-title":"N Engl J Med"},{"issue":"6","key":"1792_CR36","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type\u00a02 diabetes. N Engl J Med. 2021;385(6):503\u201315. https:\/\/doi.org\/10.1056\/NEJMoa2107519.","journal-title":"N Engl J Med"},{"issue":"3","key":"1792_CR37","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2206038.","journal-title":"N Engl J Med"},{"key":"1792_CR38","unstructured":"EMA. Mounjaro (tirzepatide). Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mounjaro-epar-product-information_en.pdf. Accessed 25 Mar 2026."},{"key":"1792_CR39","unstructured":"EMA. Wegovy (semaglutide). Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/wegovy-epar-product-information_en.pdf. Accessed 25 Mar 2026."},{"key":"1792_CR40","unstructured":"EMA. Ozempic (semaglutide). Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ozempic-epar-product-information_en.pdf. Accessed 25 Mar 2026."},{"issue":"9","key":"1792_CR41","doi-asserted-by":"publisher","first-page":"e92454","DOI":"10.7759\/cureus.92454","volume":"17","author":"OA Alsuwailem","year":"2025","unstructured":"Alsuwailem OA, Alanazi R, Almutairi HM, et al. Hair loss associated with glucagon-like peptide-1 (GLP-1) receptor agonist use: a systematic review. Cureus. 2025;17(9):e92454. https:\/\/doi.org\/10.7759\/cureus.92454.","journal-title":"Cureus"},{"issue":"5","key":"1792_CR42","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1111\/ijd.70133","volume":"65","author":"MK Branyiczky","year":"2026","unstructured":"Branyiczky MK, Lowe MS, McMullen E, Donovan J, Khosravi-Hafshejani T. Effects of GLP-1 receptor agonists on hair loss and regrowth: a systematic review. Int J Dermatol. 2026;65(5):1030\u20132. https:\/\/doi.org\/10.1111\/ijd.70133.","journal-title":"Int J Dermatol"},{"issue":"8","key":"1792_CR43","doi-asserted-by":"publisher","first-page":"e90021","DOI":"10.7759\/cureus.90021","volume":"17","author":"RF Rojas Lopez","year":"2025","unstructured":"Rojas Lopez RF, Lynett Barrera D, Amaya Mu\u00f1oz MC, Saavedra Diaz MP. Alopecia as an emerging adverse effect associated with glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss: a scoping review. Cureus. 2025;17(8):e90021. https:\/\/doi.org\/10.7759\/cureus.90021.","journal-title":"Cureus"},{"issue":"1","key":"1792_CR44","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jaad.2024.03.021","volume":"91","author":"MM Tran","year":"2024","unstructured":"Tran MM, Mirza FN, Lee AC, Goldbach HS, Libby TJ, Wisco OJ. Dermatologic findings associated with semaglutide use: a scoping review. J Am Acad Dermatol. 2024;91(1):166\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2024.03.021.","journal-title":"J Am Acad Dermatol"},{"issue":"2S","key":"1792_CR45","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.jaad.2023.04.022","volume":"89","author":"L Alhanshali","year":"2023","unstructured":"Alhanshali L, Buontempo M, Shapiro J, Lo Sicco K. Medication-induced hair loss: an update. J Am Acad Dermatol. 2023;89(2S):S20\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2023.04.022.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1792_CR46","doi-asserted-by":"publisher","first-page":"301","DOI":"10.2174\/157488606777934477","volume":"1","author":"BM Piraccini","year":"2006","unstructured":"Piraccini BM, Iorizzo M, Rech G, Tosti A. Drug-induced hair disorders. Curr Drug Saf. 2006;1(3):301\u20135. https:\/\/doi.org\/10.2174\/157488606777934477.","journal-title":"Curr Drug Saf"},{"issue":"5","key":"1792_CR47","doi-asserted-by":"publisher","first-page":"e8320","DOI":"10.7759\/cureus.8320","volume":"12","author":"F Asghar","year":"2020","unstructured":"Asghar F, Shamim N, Farooque U, Sheikh H, Aqeel R. Telogen effluvium: a review of the literature. Cureus. 2020;12(5):e8320. https:\/\/doi.org\/10.7759\/cureus.8320.","journal-title":"Cureus"},{"issue":"5","key":"1792_CR48","doi-asserted-by":"publisher","first-page":"604","DOI":"10.4103\/0378-6323.116728","volume":"79","author":"AJ Kanwar","year":"2013","unstructured":"Kanwar AJ, Narang T. Anagen effluvium. Indian J Dermatol Venereol Leprol. 2013;79(5):604\u201312. https:\/\/doi.org\/10.4103\/0378-6323.116728.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"1","key":"1792_CR49","doi-asserted-by":"publisher","first-page":"e78298","DOI":"10.7759\/cureus.78298","volume":"17","author":"YA Abarca","year":"2025","unstructured":"Abarca YA, Scott-Emuakpor R, Tirth J, et al. Alopecia areata: understanding the pathophysiology and advancements in treatment modalities. Cureus. 2025;17(1):e78298. https:\/\/doi.org\/10.7759\/cureus.78298.","journal-title":"Cureus"},{"key":"1792_CR50","doi-asserted-by":"publisher","first-page":"7349","DOI":"10.2147\/DDDT.S542000","volume":"19","author":"S Chen","year":"2025","unstructured":"Chen S, Li L, Ding W, Zhu Y, Zhou N. Androgenetic alopecia: an update on pathogenesis and pharmacological treatment. Drug Des Devel Ther. 2025;19:7349\u201363. https:\/\/doi.org\/10.2147\/DDDT.S542000.","journal-title":"Drug Des Devel Ther"},{"issue":"6","key":"1792_CR51","doi-asserted-by":"publisher","first-page":"384","DOI":"10.5021\/ad.24.043","volume":"36","author":"DH Kang","year":"2024","unstructured":"Kang DH, Kwon SH, Sim WY, Lew BL. Telogen effluvium associated with weight loss: a single center retrospective study. Ann Dermatol. 2024;36(6):384\u20138. https:\/\/doi.org\/10.5021\/ad.24.043.","journal-title":"Ann Dermatol"},{"issue":"6","key":"1792_CR52","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3949\/ccjm.76a.08080","volume":"76","author":"S Harrison","year":"2009","unstructured":"Harrison S, Bergfeld W. Diffuse hair loss: its triggers and management. Cleve Clin J Med. 2009;76(6):361\u20137. https:\/\/doi.org\/10.3949\/ccjm.76a.08080.","journal-title":"Cleve Clin J Med"},{"issue":"24","key":"1792_CR53","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1001\/jama.1976.03260500038026","volume":"235","author":"DK Goette","year":"1976","unstructured":"Goette DK, Odom RB. Alopecia in crash dieters. JAMA. 1976;235(24):2622\u20133.","journal-title":"JAMA"},{"issue":"2","key":"1792_CR54","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3390\/medicina60020325","volume":"60","author":"K Smolarczyk","year":"2024","unstructured":"Smolarczyk K, Meczekalski B, Rudnicka E, Suchta K, Szeliga A. Association of obesity and bariatric surgery on hair health. Medicina (Kaunas). 2024;60(2):325. https:\/\/doi.org\/10.3390\/medicina60020325.","journal-title":"Medicina (Kaunas)"},{"issue":"5","key":"1792_CR55","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1007\/s11695-020-04412-8","volume":"30","author":"S Ledoux","year":"2020","unstructured":"Ledoux S, Flamant M, Calabrese D, Bogard C, Sami O, Coupaye M. What are the micronutrient deficiencies responsible for the most common nutritional symptoms after bariatric surgery? Obes Surg. 2020;30(5):1891\u20137. https:\/\/doi.org\/10.1007\/s11695-020-04412-8.","journal-title":"Obes Surg"},{"issue":"4","key":"1792_CR56","doi-asserted-by":"publisher","first-page":"e14617","DOI":"10.7759\/cureus.14617","volume":"13","author":"RA Cohen-Kurzrock","year":"2021","unstructured":"Cohen-Kurzrock RA, Cohen PR. Bariatric surgery-induced telogen effluvium (Bar SITE): case report and a review of hair loss following weight loss surgery. Cureus. 2021;13(4):e14617. https:\/\/doi.org\/10.7759\/cureus.14617.","journal-title":"Cureus"},{"issue":"1","key":"1792_CR57","doi-asserted-by":"publisher","first-page":"e70070","DOI":"10.1111\/cob.70070","volume":"16","author":"J Urbina","year":"2026","unstructured":"Urbina J, Salinas-Ruiz LE, Valenciano C, Clapp B. Micronutrient and nutritional deficiencies associated with GLP-1 receptor agonist therapy: a narrative review. Clin Obes. 2026;16(1):e70070. https:\/\/doi.org\/10.1111\/cob.70070.","journal-title":"Clin Obes"},{"issue":"6","key":"1792_CR58","doi-asserted-by":"publisher","first-page":"3542","DOI":"10.1111\/dom.16368","volume":"27","author":"P Melis","year":"2025","unstructured":"Melis P, Lucijanic M, Kranjcec B, Cigrovski Berkovic M, Marusic S. The effect of semaglutide on intestinal iron absorption in patients with type\u00a02 diabetes mellitus\u2014a pilot study. Diabetes Obes Metab. 2025;27(6):3542\u20135. https:\/\/doi.org\/10.1111\/dom.16368.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"1792_CR59","doi-asserted-by":"publisher","first-page":"107587","DOI":"10.1016\/j.cdnut.2025.107587","volume":"9","author":"F Kerlikowsky","year":"2025","unstructured":"Kerlikowsky F, Kr\u00e4mer K, Eggersdorfer M, Hahn A. GLP-1 receptor agonists\u2014good for body weight, bad for micronutrient status? Curr Dev Nutr. 2025;9(11):107587. https:\/\/doi.org\/10.1016\/j.cdnut.2025.107587.","journal-title":"Curr Dev Nutr"},{"issue":"3","key":"1792_CR60","doi-asserted-by":"publisher","first-page":"e70125","DOI":"10.1111\/jocd.70125","volume":"24","author":"D Haykal","year":"2025","unstructured":"Haykal D. Alopecia and semaglutide: connecting the dots for patient safety. J Cosmet Dermatol. 2025;24(3):e70125. https:\/\/doi.org\/10.1111\/jocd.70125.","journal-title":"J Cosmet Dermatol"},{"issue":"9","key":"1792_CR61","doi-asserted-by":"publisher","first-page":"2896","DOI":"10.3390\/nu12092896","volume":"12","author":"O Jamil","year":"2020","unstructured":"Jamil O, Gonzalez-Heredia R, Quadri P, et al. Micronutrient deficiencies in laparoscopic sleeve gastrectomy. Nutrients. 2020;12(9):2896. https:\/\/doi.org\/10.3390\/nu12092896.","journal-title":"Nutrients"},{"issue":"12","key":"1792_CR62","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.1007\/s11695-018-3433-3","volume":"28","author":"G Katsogridaki","year":"2018","unstructured":"Katsogridaki G, Tzovaras G, Sioka E, et al. Hair loss after laparoscopic sleeve gastrectomy. Obes Surg. 2018;28(12):3929\u201334. https:\/\/doi.org\/10.1007\/s11695-018-3433-3.","journal-title":"Obes Surg"},{"issue":"2-3","key":"1792_CR63","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.regpep.2006.02.007","volume":"134","author":"JF List","year":"2006","unstructured":"List JF, He H, Habener JF. Glucagon-like peptide-1 receptor and proglucagon expression in mouse skin. Regul Pept. 2006;134(2\u20133):149\u201357. https:\/\/doi.org\/10.1016\/j.regpep.2006.02.007.","journal-title":"Regul Pept"},{"issue":"9","key":"1792_CR64","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1111\/ijd.17246","volume":"63","author":"DD Desai","year":"2024","unstructured":"Desai DD, Sikora M, Nohria A, et al. GLP-1 agonists and hair loss: a call for further investigation. Int J Dermatol. 2024;63(9):1128\u201330. https:\/\/doi.org\/10.1111\/ijd.17246.","journal-title":"Int J Dermatol"},{"key":"1792_CR65","doi-asserted-by":"publisher","first-page":"533","DOI":"10.4103\/jod.jod_66_21","volume":"12","author":"R Kant","year":"2021","unstructured":"Kant R, Barnwal S, Sharma SK, Thakur K. Reversal of alopecia by insulin therapy in controlled type\u00a02 DM: a case report. J Diabetol. 2021;12:533\u20137.","journal-title":"J Diabetol"},{"key":"1792_CR66","doi-asserted-by":"publisher","first-page":"109555","DOI":"10.1016\/j.biopha.2019.109555","volume":"120","author":"L Zhu","year":"2019","unstructured":"Zhu L, Zhou J, Pan Y, et al. Glucagon-like peptide-1 receptor expression and its functions are regulated by androgen. Biomed Pharmacother. 2019;120:109555. https:\/\/doi.org\/10.1016\/j.biopha.2019.109555.","journal-title":"Biomed Pharmacother"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01792-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01792-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01792-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T03:25:06Z","timestamp":1781753106000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01792-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":66,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1792"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01792-0","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"assertion":[{"value":"31 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Bianca Maria Piraccini has been a speaker and\/or consultant for Almirall, Difa Cooper, Dercos-L\u2019Oreal, Eli\u00a0Lilly, ISDIN, Legacy Healthcare, Pierre Fabre-Ducray, Giuliani, Olistic, Pfizer. Sergio Va\u00f1\u00f3-Galv\u00e1n has received honoraria for lectures and consulting fees for acting as an advisor from Pierre Fabre. Ulrike Blume-Peytavi has been a speaker and\/or consultant for Abbvie, Almirall, Cantabria Labs, Cassiopeia, CeraVe, Concert Pharmaceuticals\/Sun Pharma, Cosmopharma, Dermocosm\u00e9tique Vichy, Galderma Laboratorium GmbH, Eli\u00a0Lilly, Legacy Healthcare, LEO-Pharma, Novartis, Pfizer, Sanofi Regeneron. Virginie Ribet and Val\u00e9rie Mengeaud are employees of Pierre Fabre.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Information presented in this article is based on previously conducted studies and it does not contain data from new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}